SCHEMBL6682858

SCHEMBL6682858

NC(=O)C(=O)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 4/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TSHR P16473 1/20 0.50
GRIN2D O15399 1/20 0.50
GRIN3B O60391 1/20 0.50
GRIN1 Q05586 1/20 0.50
GRIN2A Q12879 1/20 0.50
GRIN2B Q13224 1/20 0.50
GRIN2C Q14957 1/20 0.50
GRIN3A Q8TCU5 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
MGLL Q99685 1/20 0.47
PAX8 Q06710 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 1/20 0.46
REN P00797 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25378740 0.89 LMNA (0.51) LMNAKDM4EALDH1A1NPSR1TSHR
SCHEMBL30482165 0.89 TDP1 (0.49) LMNAKDM4EALDH1A1NPSR1MEN1
SCHEMBL25376438 0.87 TSHR (0.49) LMNAKDM4EALDH1A1NPSR1TSHR
SCHEMBL25378385 0.85 KMT2A (0.58) LMNAALDH1A1TSHRKMT2A
Ammonia Solution, Strong SCHEMBL25374615 0.85 TSHR (0.48) LMNAKDM4EALDH1A1NPSR1TSHR
SCHEMBL30482084 0.85 KMT2A (0.58) LMNAALDH1A1TSHRKMT2A
SCHEMBL25378271 0.85 TAS2R14 (0.47) LMNAKDM4EALDH1A1NPSR1MEN1
SCHEMBL25376244 0.84 GRIN2D (0.51) LMNAKDM4EALDH1A1NPSR1GRIN2D
SCHEMBL25375460 0.84 L3MBTL1 (0.60) LMNAALDH1A1NPSR1TSHRMEN1
SCHEMBL25375484 0.83 HDAC1 (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024089225-A1 PROCESS FOR THE SYNTHESIS OF METHOXY SUBSTITUTED BENZALDEHYDE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2024-05-02 WO claimed
CN-115872894-A Synthesis of non-ionic contrast agents 上海慧聚药业有限公司 2023-03-31 CN claimed
CN-114456135-A Preparation of dronedarone 江苏慧聚药业股份有限公司 2022-05-10 CN claimed
CN-113461572-A Synthesis of 2- (3-bromo-5-methylphenyl) acetonitrile 江苏慧聚药业有限公司 2021-10-01 CN claimed
CN-113444052-A Synthesis of gefitinib 江苏君若药业有限公司 2021-09-28 CN claimed
CN-111303131-B Tegoprazan (Tegoprazan) analogue and synthetic method thereof 江苏慧聚药业有限公司 2021-06-04 CN claimed
CN-111303131-A Tegoprazan (Tegoprazan) analogue and synthetic method thereof 海门慧聚药业有限公司 2020-06-19 CN claimed
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
CN-119080642-A Non-neridrone key intermediate and preparation method thereof 滁州市庆云医药有限公司 2024-12-06 CN disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2024089225-A1 PROCESS FOR THE SYNTHESIS OF METHOXY SUBSTITUTED BENZALDEHYDE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2024-05-02 WO disclosed
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS University of Florida Research Foundation, Incorporation (US) 2024-02-29 US disclosed
CN-117504933-A Hydroxy-substituted pyridine-2-carboxylic acid amide ligands and their use in copper catalyzed aryl halide coupling reactions 中国科学院上海有机化学研究所 2024-02-06 CN disclosed
CN-113444052-A Synthesis of gefitinib 江苏君若药业有限公司 2021-09-28 CN disclosed
CN-111303131-B Tegoprazan (Tegoprazan) analogue and synthetic method thereof 江苏慧聚药业有限公司 2021-06-04 CN disclosed
CN-111303131-A Tegoprazan (Tegoprazan) analogue and synthetic method thereof 海门慧聚药业有限公司 2020-06-19 CN disclosed
CN-104151220-A N,N'-dialkyl dithiooxamide as well as preparation method and application thereof HUNAN CHEMAPI BIOLOG TECHNOLOGY CO LTD 2014-11-19 CN disclosed
CN-1942448-A Novel imidazoles WARNER LAMBERT CO (US) 2007-04-04 CN disclosed
WO-2004065305-A1 NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE UNIVERSITY OF DAYTON (US) 2004-08-05 WO disclosed
WO-2003060192-A1 NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 LMNA 936/4885KDM4E 1639/4885ALDH1A1 29/4885
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS FUS, SNRPE, RRBP1 LMNA 1640/4885KDM4E 1687/4885ALDH1A1 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.